Development of 2, 4-diaminoquinazoline derivatives as potent PAK4 inhibitors by the core refinement strategy
Upon analysis of the reported crystal structure of PAK4 inhibitor KY04031 (PAK4 IC50?=?0.790?μM) in the active site of PAK4, we investigated the possibility of changing the triazine core of KY04031 to a quinazoline. Using KY04031 as a starting
AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS
Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, [formula (I) should be inserted here]. Also provided herein are pharmaceutical compositions comprising compounds of Formula (I) and methods
-
(2016/11/17)
More Articles about upstream products of 685109-10-8